| Name | Title | Contact Details |
|---|
Gliknik Inc., a biopharmaceuticals company, develops therapies for patients with cancer and immune disorders.
Palleon is targeting glycan-sensing checkpoints to unleash both the innate and adaptive immune responses to cancer.
Surface Pharmaceuticals, Inc. operates as a biotechnology company. The Company develops medicine and drugs for dry eye diseases. Surface Pharmaceuticals serves customers in the State of California.
Istari Oncology, Inc. is a clinical-stage biotechnology company focused on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. The company was founded by Darell Bigner, MD, and Matthias Gromeier, MD, of Duke University Medical Center in 2016. Both are leaders in their respective research fields of virology, immunology, monoclonal development and clinical medicine, particularly in the treatment of brain tumors.
We are a global biopharmaceutical company leveraging courageous science, creativity, and compassion to deliver life-changing therapies. By pioneering targeted C3 therapies, we aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology.